Fida Bacha1, Laure El Ghormli2, Silva Arslanian3, Philip Zeitler4, Lori M Laffel5, Lorraine E Levitt Katz6, Rachelle Gandica7, Nancy T Chang8, Jennifer E Sprague9, Sarah A Macleish10. 1. Children's Nutrition Research Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. 2. Biostatistics Center, George Washington University, Rockville, Maryland. 3. UPMC, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. 4. University of Colorado Anschutz Medical Campus, Aurora, Colorado. 5. Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts. 6. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 7. Columbia University, New York, New York. 8. Children's Hospital of Los Angeles, Los Angeles, Louisiana. 9. Washington University in St. Louis, St. Louis, Missouri. 10. Case Western Reserve University, Cleveland, Ohio.
Abstract
OBJECTIVE: To understand the factors associated with glycemic control after starting insulin in youth with type 2 diabetes following glycemic failure (persistent HbA1c ≥8%) withmetformin alone, metformin + rosiglitazone or metformin + lifestyle in the TODAY study. METHODS: Change in HbA1c after add-on insulin therapy and the factors predictive of glycemic response were evaluated. At 1-year postinsulin initiation, 253 youth had a mean of 3.9 ± 1.0 visits since the time of insulin initiation. Participants were divided into three groups according to glycemic control: consistent decrease in HbA1c by ≥0.5%, change <0.5%, or consistent increase in HbA1c ≥0.5%, at 75% or more of the visits. RESULTS: Within 1-year postinsulin initiation, 33.2% of participants had a consistent HbA1c decrease of ≥0.5%, 46.2% changed HbA1c <0.5%, and 20.6% had an increase ≥0.5%. At randomization into TODAY and at time of insulin initiation, the three glycemia groups were similar in age, sex, race-ethnicity, pubertal stage, BMI z-score, diabetes duration, and insulin secretion indices. Consistent HbA1c improvement was associated with higher insulin sensitivity (1/fasting insulin) at randomization and at time of failure, higher adiponectin at randomization, and was not associated with indices of β-cell function. CONCLUSIONS: Response to add-on insulin was highly variable among youth in TODAY. Greater insulin sensitivity and higher adiponectin concentrations at randomization were associated with improved glycemic control after initiation of insulin. Due to limited information on adherence to insulin injections, the roles of adherence to the prescribed insulin regimen or psychosocial factors are unknown.
RCT Entities:
OBJECTIVE: To understand the factors associated with glycemic control after starting insulin in youth with type 2 diabetes following glycemic failure (persistent HbA1c ≥8%) with metformin alone, metformin + rosiglitazone or metformin + lifestyle in the TODAY study. METHODS: Change in HbA1c after add-on insulin therapy and the factors predictive of glycemic response were evaluated. At 1-year postinsulin initiation, 253 youth had a mean of 3.9 ± 1.0 visits since the time of insulin initiation. Participants were divided into three groups according to glycemic control: consistent decrease in HbA1c by ≥0.5%, change <0.5%, or consistent increase in HbA1c ≥0.5%, at 75% or more of the visits. RESULTS: Within 1-year postinsulin initiation, 33.2% of participants had a consistent HbA1c decrease of ≥0.5%, 46.2% changed HbA1c <0.5%, and 20.6% had an increase ≥0.5%. At randomization into TODAY and at time of insulin initiation, the three glycemia groups were similar in age, sex, race-ethnicity, pubertal stage, BMI z-score, diabetes duration, and insulin secretion indices. Consistent HbA1c improvement was associated with higher insulin sensitivity (1/fasting insulin) at randomization and at time of failure, higher adiponectin at randomization, and was not associated with indices of β-cell function. CONCLUSIONS: Response to add-on insulin was highly variable among youth in TODAY. Greater insulin sensitivity and higher adiponectin concentrations at randomization were associated with improved glycemic control after initiation of insulin. Due to limited information on adherence to insulin injections, the roles of adherence to the prescribed insulin regimen or psychosocial factors are unknown.
Authors: T C Drake; F-C Hsu; D Hire; S-H Chen; R M Cohen; R McDuffie; E Nylen; P O'Connor; S Rehman; E R Seaquist Journal: Diabetes Obes Metab Date: 2015-10-26 Impact factor: 6.577
Authors: Phil Zeitler; Kathryn Hirst; Laura Pyle; Barbara Linder; Kenneth Copeland; Silva Arslanian; Leona Cuttler; David M Nathan; Sherida Tollefsen; Denise Wilfley; Francine Kaufman Journal: N Engl J Med Date: 2012-04-29 Impact factor: 91.245
Authors: Elizabeth R Seaquist; John Anderson; Belinda Childs; Philip Cryer; Samuel Dagogo-Jack; Lisa Fish; Simon R Heller; Henry Rodriguez; James Rosenzweig; Robert Vigersky Journal: J Clin Endocrinol Metab Date: 2013-04-15 Impact factor: 5.958
Authors: Fida Bacha; Laura Pyle; Kristen Nadeau; Leona Cuttler; Robin Goland; Morey Haymond; Lynne Levitsky; Jane Lynch; Ruth S Weinstock; Neil H White; Sonia Caprio; Silva Arslanian Journal: Pediatr Diabetes Date: 2012-02-15 Impact factor: 4.866
Authors: J A Wagner; E C Wright; M M Ennis; M Prince; J Kochan; D J R Nunez; B Schneider; M-D Wang; Y Chen; S Ghosh; B J Musser; M T Vassileva Journal: Clin Pharmacol Ther Date: 2009-06-24 Impact factor: 6.875
Authors: Risa M Wolf; Andrew E Jaffe; Susana Rodriguez; Xia Lei; Dylan C Sarver; Alexander T Straub; G William Wong; Sheela N Magge Journal: Am J Physiol Endocrinol Metab Date: 2021-04-26 Impact factor: 5.900